Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S. shortages and provide an alternative source of BCG, a critical standard-of-care in bladder cancer Multiple urology centers ...

“Constrained BCG supply has improved stewardship of a limited resource but has come at a high cost to our patients,” said Dr. Chad Reichard, Co-Director of Clinical Research, Urology of Indiana.